Faculty, Staff and Student Publications
Publication Date
3-18-2025
Journal
Cell Reports Medicine
Abstract
Accurate detection of malignant transformation in oral potentially malignant disorders (OPMDs) is crucial for guiding effective treatment and improving patient management. This study evaluates the potential of MET-binding peptide-indocyanine green (cMBP-ICG), a mesenchymal-epithelial transition factor (MET)-targeted near-infrared fluorescence imaging (NIRFI) probe, for biopsy site selection in OPMDs. Preclinical results demonstrate the superior accuracy of NIRFI-assisted biopsy over conventional oral examination (COE)-based biopsy in detecting high-grade dysplasia (HGD) or squamous cell carcinoma (SCC) and reducing missed detection rates. In a clinical trial with 50 patients, NIRFI-assisted biopsy achieves significantly higher diagnostic accuracy compared to COE-based biopsy (91% vs. 72%, p = 0.0005). These findings underscore the importance of NIRFI in enhancing diagnostic precision, supporting early detection and enabling timely and accurate treatment interventions for patients with OPMDs. The clinical trial is registered under the registration number ChiCTR2300074454.
Keywords
Adult, Aged, Female, Humans, Male, Middle Aged, Biopsy, Carcinoma, Squamous Cell, Fluorescent Dyes, Indocyanine Green, Mouth Neoplasms, Optical Imaging, Proto-Oncogene Proteins c-met, Spectroscopy, Near-Infrared, oral squamous cell carcinoma, oral potentially malignant disorders, mesenchymal-epithelial transition factor, near-infrared targeted fluorescent imaging, topical application, biopsy site selection, fluorescence-guided biopsy, 4-NQO-induced OSCC model, molecular imaging
DOI
10.1016/j.xcrm.2025.101978
PMID
39999837
PMCID
PMC11970325
PubMedCentral® Posted Date
2-24-2025
PubMedCentral® Full Text Version
Post-print
Graphical Abstract
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons